{"id":"placebo-of-cdp870","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"As a placebo, this formulation is inert and produces no pharmacological effect. It is used in clinical trials as a control comparator to assess the efficacy and safety of the active drug CDP-870 (certolizumab pegol, a TNF-alpha inhibitor) against baseline and non-specific effects.","oneSentence":"This is a placebo control arm and contains no active pharmaceutical ingredient.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:09.816Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04123795","phase":"PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2020-01-21","conditions":"Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis","enrollment":49},{"nctId":"NCT06028438","phase":"PHASE2","title":"A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-08-15","conditions":"Arthritis, Rheumatoid","enrollment":103},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT01451203","phase":"PHASE3","title":"Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-10-11","conditions":"Rheumatoid Arthritis","enrollment":319},{"nctId":"NCT05930613","phase":"PHASE3","title":"Certolizumab in Recurrent Implantation Failure (RIF)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-11-30","conditions":"Recurrent Unexplained Implantation Failure","enrollment":161},{"nctId":"NCT03215277","phase":"PHASE2","title":"A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2017-10-04","conditions":"Ankylosing Spondylitis","enrollment":76},{"nctId":"NCT02552212","phase":"PHASE3","title":"Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2015-09","conditions":"Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA","enrollment":317},{"nctId":"NCT03051217","phase":"PHASE2, PHASE3","title":"A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2017-02-21","conditions":"Moderate to Severe Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis","enrollment":127},{"nctId":"NCT02346240","phase":"PHASE3","title":"Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2015-02-11","conditions":"Psoriasis, Plaque Psoriasis","enrollment":559},{"nctId":"NCT04643483","phase":"PHASE3","title":"A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease","status":"WITHDRAWN","sponsor":"UCB Biopharma SRL","startDate":"2021-06","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT02505542","phase":"PHASE3","title":"Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2015-07","conditions":"Axial Spondyloarthrithis, Ankylosing Spondylitis","enrollment":736},{"nctId":"NCT00152386","phase":"PHASE3","title":"A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-02","conditions":"Rheumatoid Arthritis","enrollment":950},{"nctId":"NCT00160602","phase":"PHASE3","title":"A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-06","conditions":"Rheumatoid Arthritis","enrollment":590},{"nctId":"NCT00291668","phase":"PHASE2","title":"Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-03-02","conditions":"Crohn's Disease","enrollment":94},{"nctId":"NCT01864265","phase":"PHASE3","title":"Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2013-07","conditions":"Rheumatoid Arthritis","enrollment":156},{"nctId":"NCT02326298","phase":"PHASE3","title":"An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2014-12-16","conditions":"Psoriasis, Plaque Psoriasis","enrollment":234},{"nctId":"NCT02326272","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2014-12-15","conditions":"Psoriasis, Plaque Psoriasis","enrollment":227},{"nctId":"NCT00329303","phase":"PHASE2","title":"Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-04","conditions":"Psoriasis","enrollment":71},{"nctId":"NCT00245765","phase":"PHASE2","title":"Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-10","conditions":"Chronic Plaque Psoriasis","enrollment":176},{"nctId":"NCT00349752","phase":"PHASE3","title":"Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease","status":"TERMINATED","sponsor":"UCB Pharma","startDate":"2006-11","conditions":"Crohn's Disease","enrollment":174},{"nctId":"NCT00552058","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2008-03","conditions":"Crohn Disease","enrollment":439},{"nctId":"NCT00308581","phase":"PHASE3","title":"Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-04","conditions":"Crohn's Disease","enrollment":539},{"nctId":"NCT00580840","phase":"PHASE4","title":"Dosing Flexibility Study in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2007-12","conditions":"Rheumatoid Arthritis","enrollment":333},{"nctId":"NCT01087762","phase":"PHASE3","title":"Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2010-03","conditions":"Spondyloarthropathies","enrollment":325},{"nctId":"NCT00717236","phase":"PHASE3","title":"Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2008-07","conditions":"Rheumatoid Arthritis","enrollment":1648},{"nctId":"NCT00993668","phase":"PHASE4","title":"Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2009-09","conditions":"Rheumatoid Arthritis","enrollment":224},{"nctId":"NCT01087788","phase":"PHASE3","title":"Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2010-03","conditions":"Arthritis, Psoriatic","enrollment":409},{"nctId":"NCT01521923","phase":"PHASE3","title":"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2012-01","conditions":"Rheumatoid Arthritis","enrollment":359},{"nctId":"NCT01519791","phase":"PHASE3","title":"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-01","conditions":"Rheumatoid Arthritis","enrollment":880},{"nctId":"NCT01500278","phase":"PHASE4","title":"Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2011-12","conditions":"Rheumatoid Arthritis","enrollment":915},{"nctId":"NCT02151851","phase":"PHASE3","title":"A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Pharma SA, Belgium","startDate":"2014-07","conditions":"Rheumatoid Arthritis","enrollment":430},{"nctId":"NCT02862574","phase":"PHASE2","title":"Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-12-15","conditions":"Rheumatoid Arthritis","enrollment":15},{"nctId":"NCT02497976","phase":"PHASE3","title":"Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis","status":"COMPLETED","sponsor":"ICStudy, LLC","startDate":"2015-12-15","conditions":"Cystitis, Interstitial","enrollment":42},{"nctId":"NCT02430909","phase":"PHASE2","title":"Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Celltech","startDate":"2015-04","conditions":"Rheumatoid Arthritis","enrollment":159},{"nctId":"NCT02365948","phase":"PHASE1","title":"A Study of Certolizumab Pegol to Evaluate Pharmacokinetics and Safety in Adult Healthy Chinese Subjects","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2015-03","conditions":"Healthy Subjects","enrollment":36},{"nctId":"NCT00329550","phase":"PHASE2","title":"Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","startDate":"2006-05","conditions":"Crohn's Disease","enrollment":40},{"nctId":"NCT00329420","phase":"PHASE2","title":"Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-05","conditions":"Crohn's Disease","enrollment":46},{"nctId":"NCT01147341","phase":"PHASE4","title":"Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia","status":"COMPLETED","sponsor":"Michael Schiff, MD","startDate":"2010-07","conditions":"Rheumatoid Arthritis","enrollment":37},{"nctId":"NCT02132234","phase":"PHASE4","title":"Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis","status":"UNKNOWN","sponsor":"Jagiellonian University","startDate":"2013-06","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis","enrollment":100},{"nctId":"NCT00152425","phase":"PHASE3","title":"Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-02","conditions":"Crohn's Disease","enrollment":392},{"nctId":"NCT00152490","phase":"PHASE3","title":"A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2003-12","conditions":"Crohn's Disease","enrollment":604},{"nctId":"NCT00548834","phase":"PHASE3","title":"Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2003-06","conditions":"Rheumatoid Arthritis","enrollment":220},{"nctId":"NCT01817972","phase":"PHASE3","title":"Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease","status":"UNKNOWN","sponsor":"Gastroenterology Research of America","startDate":"2013-03","conditions":"Crohn's Disease","enrollment":65},{"nctId":"NCT00993317","phase":"PHASE3","title":"A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2009-10","conditions":"Rheumatoid Arthritis","enrollment":127},{"nctId":"NCT00791999","phase":"PHASE2, PHASE3","title":"Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2008-11","conditions":"Rheumatoid Arthritis","enrollment":316},{"nctId":"NCT00791921","phase":"PHASE3","title":"Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2008-11","conditions":"Rheumatoid Arthritis","enrollment":230},{"nctId":"NCT00674362","phase":"PHASE3","title":"Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2008-06","conditions":"Rheumatoid Arthritis","enrollment":194},{"nctId":"NCT01091220","phase":"PHASE1","title":"Evaluation of the Effects of Certolizumab Pegol on Semen Quality in Healthy Male Volunteers","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2010-03","conditions":"Sperm Quality","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of CDP870","genericName":"Placebo of CDP870","companyName":"Otsuka Pharmaceutical Co., Ltd.","companyId":"otsuka","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}